Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 123

Results For "NDA"

3670 News Found

Evonik Vland Biotech JV commences operations
Biotech | March 16, 2024

Evonik Vland Biotech JV commences operations

Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China


Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery
News | March 16, 2024

Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery

More than 10,000 scientific publications containing EUDRAGIT


Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility
Drug Approval | March 16, 2024

Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility

The company is confident of addressing the concern raised by the USFDA


Indranil Sen, CFO, Biocon resigned
People | March 16, 2024

Indranil Sen, CFO, Biocon resigned

Sen spent a decade with Biocon and held various key roles,


Cureskin secures US$ 20 million in Series B funding
News | March 14, 2024

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India


Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
Drug Approval | March 14, 2024

Zydus receives USFDA final approval for chlorpromazine hydrochloride injection

Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders


Venus Remedies gets huge global acclaim with UNICEF GMP approval
News | March 12, 2024

Venus Remedies gets huge global acclaim with UNICEF GMP approval

Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF


AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine
News | March 12, 2024

AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.


USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children
Drug Approval | March 12, 2024

USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications